DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
DongKoo Bio & Pharma Co Ltd
KOSDAQ:006620
|
KR |
|
Inversa Prime Socimi SA
MAD:YIPS
|
ES |
|
Sydbank A/S
CSE:SYDB
|
DK |
|
Guanajuato Silver Company Ltd
XTSX:GSVR
|
CA |
|
M
|
Marks and Spencer Group PLC
OTC:MAKSY
|
UK |
|
O
|
Ocean Bio-Chem Inc
F:OBC
|
US |
|
Perseus Mining Ltd
ASX:PRU
|
AU |
|
T
|
Titanium Sands Ltd
ASX:TSL
|
AU |
|
Nuvo Pharmaceuticals Inc
TSX:MRV
|
CA |
|
L
|
L'Oreal SA
XETRA:LOR
|
FR |
|
Apple Hospitality REIT Inc
NYSE:APLE
|
US |
|
Hipages Group Holdings Ltd
ASX:HPG
|
AU |
|
M
|
Max India Ltd
NSE:MAXIND
|
IN |
|
Denny's Corp
NASDAQ:DENN
|
US |
|
Wilmar International Ltd
SGX:F34
|
SG |
|
Fifth District Bancorp Inc
NASDAQ:FDSB
|
US |
|
Take And Give Needs Co Ltd
TSE:4331
|
JP |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is DongKoo Bio & Pharma Co Ltd's stock price target?
Not Available
DongKoo Bio & Pharma Co Ltd doesn't have any price targets made by Wall Street professionals.
What is DongKoo Bio & Pharma Co Ltd's Revenue forecast?
Projected CAGR
-14%
For the last 10 years the compound annual growth rate for DongKoo Bio & Pharma Co Ltd's revenue is 12%. The projected CAGR for the next 3 years is -14%.
What is DongKoo Bio & Pharma Co Ltd's Operating Income forecast?
Projected CAGR
-12%
For the last 10 years the compound annual growth rate for DongKoo Bio & Pharma Co Ltd's operating income is 4%. The projected CAGR for the next 3 years is -12%.
What is DongKoo Bio & Pharma Co Ltd's Net Income forecast?
Projected CAGR
67%
For the last 10 years the compound annual growth rate for DongKoo Bio & Pharma Co Ltd's net income is 14%. The projected CAGR for the next 3 years is 67%.
